Syndicate Bio, a pioneering biotech startup based in Nigeria, has forged a groundbreaking collaboration with SOPHiA GENETICS, a prominent cloud-based healthcare software company specializing in data-driven medicine, to bring genomic profiling and liquid biopsy services to Africa’s healthcare sector, marking a milestone in the continent’s healthcare landscape. Founded in September, Syndicate Bio collaborates with key sectors like government bodies, pharmaceutical companies, and academic institutions.
Stay well-informed and be the very first to receive all the most recent updates directly in your email! Tap here to join now for free!
The aim is to bolster the role of precision medicine locally while compiling critical datasets to advance global health and expedite drug discovery and development processes.
In a significant move, Syndicate Bio announced a key alliance with the National Institute for Cancer Research and Treatment (NICRAT) in November to launch the Cancer Genome Nigeria project. This collaboration integrates novel genomic profiling and liquid biopsy technologies, complementing the efforts of SOPHiA GENETICS and the Memorial Sloan Kettering Cancer Center (MSK) to promote health equity worldwide. The collaboration facilitates the adoption of next-generation sequencing technologies in oncology and liquid biopsy, offering a significant opportunity to advance cancer treatment and research on the continent.
Stay well-informed and be the very first to receive all the most recent updates directly in your email! Tap here to join now for free!
